Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark.
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
Eli Lilly, Qualcomm, Rumble: Market Minute
Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute.
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...
Eli Lilly to test weight loss drug Zepbound to treat addiction
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
ABC News6d
FDA: Knockoff versions of Lilly obesity drug must come off the market
The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become ...